ArticleJournal of cancer research and clinical oncology2026
Timosaponin AIII-based liposomes loaded with Auranofin for the induction of ferroptosis in anaplastic thyroid carcinoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeAnaplastic thyroid carcinoma (ATC) is an exceptionally aggressive malignancy that, despite accounting for only 1%-1.5% of all thyroid cancers, is responsible for over half of thyroid cancer-related deaths. Characterized by limited treatment options and a poor prognosis, ATC presents a critical clinical challenge. In this study, we developed and evaluated an innovative liposomal system (T-AUF-LPs) co-loading Auranofin (AUF) and Timosaponin AIII (TAIII) aimed at inducing ferroptosis in ATC cells.
methodsT-AUF-LPs were prepared via the film-hydration method and their physicochemical properties were characterized. Cellular uptake, anti-proliferative effects, and ferroptosis-related mechanisms-including reactive oxygen species (ROS), iron levels, glutathione (GSH), GPX4, ACSL4, and NCOA4-were assessed in CAL-62 and 8505C ATC cell lines. In vivo antitumor efficacy and biosafety were evaluated using a BALB/c nude mouse xenograft model.
resultsT-AUF-LPs showed superior physicochemical properties compared to conventional liposomes, including uniform spherical morphology, reduced particle size, and enhanced encapsulation efficiency. Cellular assays revealed significantly improved uptake of T-AUF-LPs in both ATC cell lines. The formulation inhibited cell proliferation in a dose-dependent manner, an effect effectively reversed by ferrostatin-1, confirming ferroptosis as the primary cell death mechanism. Mechanistic investigations indicated that T-AUF-LPs treatment increased intracellular ROS and iron levels, depleted GSH, and induced upregulation of ACSL4 and NCOA4 along with downregulation of GPX4. In vivo evaluation demonstrated effective tumor growth suppression with an excellent safety profile and no significant organ toxicity.
conclusionT-AUF-LPs exert potent anti-tumor effects by inducing ferroptosis without causing systemic organ toxicity. They represent a promising therapeutic strategy for ATC, thereby addressing a critical unmet need in the management of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.